Trial reportPsychiatry and clinical neurosciences2025
Efficacy and safety of a digital therapeutic for alcohol dependence: A multicenter, open-label, randomized controlled trial.
Trial report in Psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Facial emotional expression in response to alcohol-promoting commercials in individuals with alcohol use disorder: A pilot study.PCN reports : psychiatry and clinical neurosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimDigital therapeutics (DTx) is an emerging treatment modality for enhancing psychosocial interventions via software programs, such as smartphone applications (apps). We developed a DTx named ALM-003 to support treatment for people with alcohol dependence who are pursuing reduced drinking goals. ALM-003 was designed to promote behavioral change through daily self-monitoring with personalized feedback, interactive psychoeducational modules, and automated treatment support tools for both patients and physicians. In this multicenter, open-label, randomized controlled trial (RCT), we aimed to evaluate the efficacy and safety of ALM-003 in various clinical settings.
methodsIn this RCT, participants with alcohol dependence without serious physical, mental, or social problems due to excessive drinking, and exhibiting high or very high drinking risk levels were randomized into an intervention group (psychosocial intervention enhanced by ALM-003) or a control group (psychosocial intervention with a basic drinking diary app) for 24 weeks. The primary outcome was the change in the number of heavy drinking days (HDDs) over 28 days (Week 0 to Week 12).
resultsData analysis of the primary outcome for 136 intervention and 142 control participants was performed. Baseline HDDs were 23.2 and 23.1 days/28 days in the intervention and control groups, respectively. [Correction added on 3 September 2025, after first online publication: The values of the baseline HDDs in the preceding sentence have been corrected from '19.4 and 19.1 days' to '23.2 and 23.1 days'.] At Week 12, the intervention and control groups showed a reduction in HDDs of -12.2 and -9.5 days from baseline, with a between-group difference of -2.79 days/28 days (95% confidence interval: -4.67 to -0.90; P = 0.004). Adverse events occurred in 32.9% of participants in the intervention group and 33.6% in the control group. No adverse events were attributed to app use.
conclusionALM-003 demonstrated efficacy in reducing heavy drinking days among people with alcohol dependence at a high or very high drinking risk. CLINICAL
trial registrationThe trial design was prospectively registered with the Japan Registry of Clinical Trials (jRCT) (https://jrct.niph.go.jp/). The trial identifier is jRCT2032220560.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.